Alaunos Therapeutics Inc

Alaunos Therapeutics Inc(TCRT)の株式分析

$1.605

-0.053 (-3.31%)終値時点

Loading chart…
High
1.710
Open
1.660
VWAP
1.62
Vol
35.68K
Mkt Cap
11.53M
Low
1.550
Amount
57.86K
EV/EBITDA, TTM
0.00

Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.

alaunos.com

AI analysis of Alaunos Therapeutics Inc (TCRT)

sell

Alaunos Therapeutics Inc is not a good buy right now due to its current price of 1.605, a very low RSI of 16.85 indicating oversold conditions, and a significant year-to-date decline of 51.07%. The company is facing ongoing financial losses, with a reported Q2 loss of $952,000, and a forward P/E ratio of 18.48 suggests overvaluation relative to its earnings potential.

バリュエーション指標

The current forward P/E ratio for Alaunos Therapeutics Inc (TCRT) is 18.48, compared to its 5-year average forward P/E of 0.41.

Forward P/E

Strongly Overvalued
5Y Average P/E
0.41
Current P/E
18.48
割高
8.45
割安
-7.63

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
0.02
Current EV/EBITDA
0.00
割高
0.11
割安
-0.07

Forward P/S

Fair
5Y Average P/S
3813.34
Current P/S
0.00
割高
14290.07
割安
-6663.40

Alphio AI Price Scenarios for TCRT

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%TCRT

$3.93

シナリオ価格

B

Base

Base · 50%TCRT

$3.76

シナリオ価格

B

Bear

Bear · 25%TCRT

$3.71

シナリオ価格

イベントタイムライン

2026-05-26 (ET)

11:10:00

Alaunos Therapeutics Reports Preclinical Readout for ALN1003

2026-05-18 (ET)

08:30:00

Alaunos Therapeutics Updates Preclinical Data on ALN1003

2026-05-04 (ET)

16:40:00

Valion Bio Appoints Melinda Lackey as General Counsel

2026-03-02 (ET)

06:40:00

Alaunos Therapeutics Releases Early Data on ALN1003

2025-06-23 (ET)

08:05:06

Alaunos prices 610,399 shares at $3.36 in registered direct offering

ニュース

TCRT FAQ — answered by Alphio AI

Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Alaunos Therapeutics Inc is not a good buy right now due to its current price of 1.605, a very low RSI of 16.85 indicating oversold conditions, and a significant year-to-date decline of 51.07%. The company is facing ongoing financial losses, with a reported Q2 loss of $952,000, and a forward P/E ratio of 18.48 suggests overvaluation relative to its earnings potential.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める